NDAORALCAPSULE
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALZENNA (talazoparib) is an oral small-molecule PARP inhibitor approved by FDA in March 2024. The mechanism of action involves inhibition of poly(ADP-ribose) polymerase to induce DNA damage and cell death in cancer cells. It is indicated for patients with specific genomic alterations, particularly BRCA mutations and other homologous recombination repair deficiencies.
Growth5.3 years to LOE
Recent FDA approval positions TALZENNA in early growth phase; commercial teams are scaling launch infrastructure with expanding patient identification and provider education efforts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Korea Post Marketing Surveillance (PMS) Study of Talzenna®
Started Jun 2027
600 enrolled
Breast Neoplasms
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Started May 2026
126 enrolled
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.
Started Jul 2025
1 enrolled
Prostate Cancer
A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
Started Apr 2025
3 enrolled
Breast Cancer
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Started Apr 2023
33 enrolled
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Worked on TALZENNA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.